World-First Inhaled COVID-19 Vaccine, Developed in Partnersh

Late in 2021, Aerogen (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO's Recombinant

Related Keywords

China , Shanghai , United States , Xuefeng , Hunan , Tianjin , Ireland , Chinese , America , Mac Giolla Eain , Leo Clancy , John Power , Declan Slemon , Dan Han , Aerogen Ltd , National Medical Products Administration Of China , Global Efficacy Study Group , Science Committee , International Society Of Aerosols , Global Initiative For The Diagnosis , Novel Coronavirus Vaccine Convidecia Air , Business Wire , Emergency Use Authorization , National Medical Products Administration , Convidecia Air , Latin America , Chief Executive Officer , Enterprise Ireland , Recombinant Novel Coronavirus Vaccine , Adenovirus Type , Aerogen Solo , Efficacy Study , Respir Med , Infect Dis , Solo System Instruction , Aerosol Related Risk , International Society , Chronic Obstructive Lung Disease , Committee Report , Aerosol Therapy Emissions , Mechanical Ventilation , Vitro Assessment , Tidal Volume , Aerosol Air Qual Res , Ventilation Parameters , World , First , Inhaled , Covid , Vaccine , Eveloped , Partnership , Between , Aerogen , Cansinobio , Public , Rooster , Immunization ,